Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-FC335
- Development stage
- Preclinical
- Lead developer
- FindCure Biosciences
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
177Lu-FC335 is a therapeutic radionuclide drug conjugate (RDC) developed by FindCure Biosciences. It consists of a peptide ligand targeting fibroblast activation protein alpha (FAPα) conjugated to the therapeutic beta-emitting radioisotope lutetium-177 (177Lu). FAPα is highly expressed in the tumor microenvironment of various solid tumors, including pancreatic, lung, esophageal, and gastric cancers, but has low expression in normal tissues. By binding to FAPα, 177Lu-FC335 delivers targeted radiation directly to the tumor stroma, inducing DNA damage and cell death in FAPα-positive solid tumors. The candidate has entered investigator-initiated trials (IIT) in China.
- Other names
- 177Lu-labeled FC335Lu-177-FC335Lu177-FC335Lu 177-FC335
02
Targets
FAP (Fibroblast activation protein alpha)DNA
Beyond the preview
Go deeper on 177Lu-FC335.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-FC335.